RAPT Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of premium on marketable securities
Accretion of discounts on marketable securities
Depreciation and amortization
Stock-based compensation expense
Loss on disposal of capital equipment
Loss on foreign currency translation
Non-cash interest income, net
Non-cash operating lease expense

Changes in operating assets and liabilities:
Prepaid expenses and other assets
Accounts payable, accrued expenses and other current liabilities
Deferred revenue
Deferred rent, net of current portion
License fees payable
Operating lease liabilities
Net cash used in operating activities
Investing activities
Purchase of marketable securities
Proceeds from maturities of marketable securities
Proceeds from sale of equipment
Purchase of property and equipment
Net cash provided by investing activities
Financing activities
Proceeds from sale of common stock and pre-funded warrants in a private placement, net of issuance costs
Proceeds from issuances of common stock in "at-the-market" offerings, net of issuance costs
Public Offering
At The Market
Total proceeds from issuances of common stock in "at-the-market" offerings, net of issuance costs
Proceeds from the sale of convertible preferred stock, net of issuance costs
Proceeds from exercise of stock options, net of repurchases
Proceeds from issuance of common stock under employee stock plans
Net cash provided by financing activities

Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash paid for income taxes
Convertible preferred stock converted to common stock
Forgiveness of promissory notes from related party for purchase of common stock
Offering costs included in accounts payable
Offering costs included in accounts payable and accrued expenses
Right-of-use asset obtained in exchange for lease obligation

Comments